Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,382.00
Bid: 12,380.00
Ask: 12,382.00
Change: 264.00 (2.18%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE: UK's Gove Warns EU After Brussels Puts Brakes On Jabs Movement

Fri, 29th Jan 2021 21:45

(Alliance News) - The UK government has warned the EU it is considering action after the bloc imposed export controls on coronavirus vaccines and impinged on the post-Brexit deal on Northern Ireland.

Cabinet Office Minister Michael Gove spoke to the EU on Friday to express concern at its triggering of an aspect of the Northern Ireland Protocol to stop the unimpeded flow of jabs from the bloc into the region.

Downing Street warned the EU "as a friend and ally" not to disrupt the supply of vaccines, as the bloc took the surprise step while embroiled in a row with pharmaceutical giant AstraZeneca PLC over shortfalls in the delivery of jabs.

Northern Ireland's First Minister Arlene Foster described Brussels' move as an "incredible act of hostility" that places a "hard border" between the region and the Republic of Ireland.

She demanded a "robust response" from the UK government and spoke with Prime Minister Boris Johnson and Gove as the EU provoked widespread condemnation from across the political spectrum by triggering Article 16 of the protocol.

Gove, the chancellor of the Duchy of Lancaster, or CDL, spoke to his counterpart on the EU-UK Joint Committee, Maros Sefcovic, to "express the UK's concern over a lack of notification from the EU about its actions in relation to the NI protocol".

"CDL said the UK would now be carefully considering next steps," a statement from Downing Street added.

No 10 added that it was "urgently seeking an explanation" from the EU and "assurances as to its intentions", as the government reiterated the need to preserve the commitments of the Good Friday Agreement.

"The UK has legally-binding agreements with vaccine suppliers and it would not expect the EU, as a friend and ally, to do anything to disrupt the fulfilment of these contracts," a statement added.

The protocol, which is part of the Withdrawal Agreement, is designed to allow the free movement of goods from the EU into Northern Ireland, and prevent the need for a hard border on the island of Ireland.

But triggering Article 16 temporarily places export controls on the movement of vaccines, a move taken by the EU to prevent the region being used as a back door to move coronavirus vaccines from the bloc into the UK.

The European Commission's new regulation states: "This is justified as a safeguard measure pursuant to Article 16 of that protocol in order to avert serious societal difficulties due to a lack of supply threatening to disturb the orderly implementation of the vaccination campaigns in the member states."

It was not immediately clear what steps the government was considering, but Culture Minister Caroline Dinenage did not rule out the UK invoking Article 16 in retaliation.

"The stakes are really high and everybody needs to keep their heads about them," she said on BBC Radio 4's Any Questions?, as she assured "we're very confident in our supplies".

Archbishop of Canterbury the Justin Welby urged the EU to rethink its actions.

"Seeking to control the export of vaccines undercuts the EU's basic ethics. They need to work together with others," he tweeted.

Ireland's Premier Micheal Martin expressed his concerns to European Commission President Ursula von der Leyen.

Foster said: "At the first opportunity, the EU has placed a hard border between Northern Ireland and the Republic of Ireland over the supply chain of the coronavirus vaccine."

Shadow Northern Ireland Secretary Louise Haigh said the EU's move is "deeply destabilising" and urged the EU to "revoke this action".

"Unilateral actions like this do nothing to aid the stability in Northern Ireland which the protocol was designed to preserve," the Labour MP said.

Simon Hoare, chaor of the Commons Northern Ireland Affairs Committee, said it was "unconscionable folly" for the EU to escalate its vaccines row by triggering the protocol, adding: "We need calm, stability and level-headedness."

Northern Ireland Secretary Brandon Lewis said the region receives its vaccines as part of UK procurement.

But preventing vaccines made with the EU from being exported could hinder the UK's access to further supplies, particularly to the Belgian-made Pfizer Inc jab.

Brussels has also demanded doses of the AstraZeneca vaccine manufactured in British plants in order to solve its supply shortage issues, as member states were forced to pause or delay their rollouts.

The EU's "vaccine export transparency mechanism" will be used until the end of March to control vaccine shipments to nations outside the bloc.

It seeks to ensure that any exporting company based in the EU first submits its plans to national authorities.

European Commission Executive Vice-President Valdis Dombrovskis told a Brussels press conference: "Today the commission has adopted an implementing regulation making the export of certain products subject to an export authorisation.

"This regulation concerns the transparency and export of Covid-19 vaccines."

The UK was not named among countries exempted from the new measures.

Meanwhile, AstraZeneca published a redacted version of its contract with the EU, which the bloc said was important for "accountability".

The contract mentions that the firm would use "best reasonable efforts" to use European plants, including two in the UK, as production sites for vaccines destined for the EU.

The row intensified as the European Medicines Agency authorised the AstraZeneca jab, which it developed with Oxford University, for all adults throughout the EU.

German authorities had earlier said there was "not sufficient data to assess the vaccination effectiveness from 65 years" in only recommending its use on younger citizens.

But the EMA said that while there is not yet enough data from those aged over 55, protection is expected, and ruled that the jab can be used in older adults.

Oxford Vaccine Group Director Andrew Pollard said "there's no reason to be concerned" about using the vaccine on older citizens.

"We're quite confident because the immune responses are so similar that we will see immune responses in the same way as we have in younger adults," he said.

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.